BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 16763820)

  • 21. Comparison of 68Ga-DOTATOC biodistribution in patients with and without spleenectomy.
    Kratochwil C; Mavriopoulou E; Rath D; Afshar-Oromieh A; Apostolopoulos D; Haufe S; Mier W; Haberkorn U; Giesel FL
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):116-20. PubMed ID: 24382404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does the pretherapeutic tumor SUV in 68Ga DOTATOC PET predict the absorbed dose of 177Lu octreotate?
    Ezziddin S; Lohmar J; Yong-Hing CJ; Sabet A; Ahmadzadehfar H; Kukuk G; Biersack HJ; Guhlke S; Reichmann K
    Clin Nucl Med; 2012 Jun; 37(6):e141-7. PubMed ID: 22614212
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.
    Kwekkeboom DJ; Kooij PP; Bakker WH; Mäcke HR; Krenning EP
    J Nucl Med; 1999 May; 40(5):762-7. PubMed ID: 10319747
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic PET 18F-FDG studies in patients with primary and recurrent soft-tissue sarcomas: impact on diagnosis and correlation with grading.
    Dimitrakopoulou-Strauss A; Strauss LG; Schwarzbach M; Burger C; Heichel T; Willeke F; Mechtersheimer G; Lehnert T
    J Nucl Med; 2001 May; 42(5):713-20. PubMed ID: 11337565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors.
    Kratochwil C; Giesel FL; López-Benítez R; Schimpfky N; Kunze K; Eisenhut M; Kauczor HU; Haberkorn U
    Clin Cancer Res; 2010 May; 16(10):2899-905. PubMed ID: 20460485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
    Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prospective Within-Patient Assessment of the Impact of an Unlabeled Octreotide Pre-dose on the Biodistribution and Tumor Uptake of
    Lodge MA; Solnes LB; Chaudhry MA; Wahl RL
    Mol Imaging Biol; 2021 Oct; 23(5):766-774. PubMed ID: 33829361
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detectability of hypervascularity in early dynamic PET depends on tracer kinetics: 18 F-FDG versus 68 Ga-DOTATOC in hepatic NET metastasis.
    Sänger P; Schierz JH; Marlowe RJ; Freesmeyer M
    Liver Int; 2014 Jan; 34(1):161. PubMed ID: 23663248
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
    Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the role of [18F]FDG-PET/CT and [68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids.
    Jindal T; Kumar A; Venkitaraman B; Meena M; Kumar R; Malhotra A; Dutta R
    Cancer Imaging; 2011 Jun; 11(1):70-5. PubMed ID: 21697027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-to-Blood Ratio for Assessment of Somatostatin Receptor Density in Neuroendocrine Tumors Using
    Ilan E; Velikyan I; Sandström M; Sundin A; Lubberink M
    J Nucl Med; 2020 Feb; 61(2):217-221. PubMed ID: 31302632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inflammation-Based Index and
    Pauwels E; Van Binnebeek S; Vandecaveye V; Baete K; Vanbilloen H; Koole M; Mottaghy FM; Haustermans K; Clement PM; Nackaerts K; Van Cutsem E; Verslype C; Deroose CM
    J Nucl Med; 2020 Jul; 61(7):1014-1020. PubMed ID: 31806775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 18F-FDG kinetics and gene expression in giant cell tumors.
    Strauss LG; Dimitrakopoulou-Strauss A; Koczan D; Bernd L; Haberkorn U; Ewerbeck V; Thiesen HJ
    J Nucl Med; 2004 Sep; 45(9):1528-35. PubMed ID: 15347720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of 68Ga-DOTA-D-Phe1-Tyr3-octreotide kinetics in patients with meningiomas.
    Henze M; Dimitrakopoulou-Strauss A; Milker-Zabel S; Schuhmacher J; Strauss LG; Doll J; Mäcke HR; Eisenhut M; Debus J; Haberkorn U
    J Nucl Med; 2005 May; 46(5):763-9. PubMed ID: 15872348
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
    Kowalski J; Henze M; Schuhmacher J; Mäcke HR; Hofmann M; Haberkorn U
    Mol Imaging Biol; 2003; 5(1):42-8. PubMed ID: 14499161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 64Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with 68Ga-DOTATOC in 60 Patients.
    Malmberg C; Ripa RS; Johnbeck CB; Knigge U; Langer SW; Mortensen J; Oturai P; Loft A; Hag AM; Kjær A
    J Nucl Med; 2015 Dec; 56(12):1895-900. PubMed ID: 26429961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnostic performances of 68Ga-DOTATOC versus 18Fluorodeoxyglucose positron emission tomography in pulmonary carcinoid tumours and interrelationship with histological features.
    Lococo F; Rapicetta C; Mengoli MC; Filice A; Paci M; Di Stefano T; Coruzzi C; Versari A
    Interact Cardiovasc Thorac Surg; 2019 Jun; 28(6):957-960. PubMed ID: 30753507
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
    Giesel FL; Stefanova M; Schwartz LH; Afshar-Oromieh A; Eisenhut M; Haberkorn U; Kratochwil C
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):171-6. PubMed ID: 23370092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.